Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer

Shigeki Umemura; Daizo Kishino; Masahiro Tabata; Katsuyuki Kiura; Katsuyuki Hotta; Kenji Nishii; Yasushi Tanimoto; Arihiko Kanehiro; Kenji Notohara; Hiroshi Ueoka; Mitsune Tanimoto

doi:10.2169/internalmedicine.44.979

Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer

Shigeki Umemura, Daizo Kishino, Masahiro Tabata, Katsuyuki Kiura, Katsuyuki Hotta, Kenji Nishii, Yasushi Tanimoto, Arihiko Kanehiro, Kenji Notohara, Hiroshi Ueoka, Mitsune Tanimoto

University Hospital

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

We describe a 55-year-old man with advanced adenocarcinoma of the lung who received gefitinib ('IRESSA'). After gefitinib administration for 7 months, computed tomography scan of the chest demonstrated diffuse ground glass opacity and he was suspected to have developed gefitinib-induced interstitial lung disease (ILD). However, transbronchial lung biopsy (TBLB) revealed tumor cells in the middle-size lung vessels. Afterwards, multiple infarctions of the brain, spleen and left kidney were detected. Then, he was considered to have developed systemic tumor emboli, a rare complication. The clinical presentation of this patient was difficult to discriminate from that of ILD, and TBLB was useful in the differential diagnosis.

Original language	English
Pages (from-to)	979-982
Number of pages	4
Journal	Internal Medicine
Volume	44
Issue number	9
DOIs	https://doi.org/10.2169/internalmedicine.44.979
Publication status	Published - Oct 28 2005

Keywords

Gefitinib
Ground glass opacity
NSCLC
Transbronchial lung biopsy
Tumor embolism

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.44.979

Cite this

@article{451452208d91400a823c66fc7ffddd6c,

title = "Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer",

abstract = "We describe a 55-year-old man with advanced adenocarcinoma of the lung who received gefitinib ('IRESSA'). After gefitinib administration for 7 months, computed tomography scan of the chest demonstrated diffuse ground glass opacity and he was suspected to have developed gefitinib-induced interstitial lung disease (ILD). However, transbronchial lung biopsy (TBLB) revealed tumor cells in the middle-size lung vessels. Afterwards, multiple infarctions of the brain, spleen and left kidney were detected. Then, he was considered to have developed systemic tumor emboli, a rare complication. The clinical presentation of this patient was difficult to discriminate from that of ILD, and TBLB was useful in the differential diagnosis.",

keywords = "Gefitinib, Ground glass opacity, NSCLC, Transbronchial lung biopsy, Tumor embolism",

author = "Shigeki Umemura and Daizo Kishino and Masahiro Tabata and Katsuyuki Kiura and Katsuyuki Hotta and Kenji Nishii and Yasushi Tanimoto and Arihiko Kanehiro and Kenji Notohara and Hiroshi Ueoka and Mitsune Tanimoto",

year = "2005",

month = oct,

day = "28",

doi = "10.2169/internalmedicine.44.979",

language = "English",

volume = "44",

pages = "979--982",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "9",

}

TY - JOUR

T1 - Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer

AU - Umemura, Shigeki

AU - Kishino, Daizo

AU - Tabata, Masahiro

AU - Kiura, Katsuyuki

AU - Hotta, Katsuyuki

AU - Nishii, Kenji

AU - Tanimoto, Yasushi

AU - Kanehiro, Arihiko

AU - Notohara, Kenji

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

PY - 2005/10/28

Y1 - 2005/10/28

N2 - We describe a 55-year-old man with advanced adenocarcinoma of the lung who received gefitinib ('IRESSA'). After gefitinib administration for 7 months, computed tomography scan of the chest demonstrated diffuse ground glass opacity and he was suspected to have developed gefitinib-induced interstitial lung disease (ILD). However, transbronchial lung biopsy (TBLB) revealed tumor cells in the middle-size lung vessels. Afterwards, multiple infarctions of the brain, spleen and left kidney were detected. Then, he was considered to have developed systemic tumor emboli, a rare complication. The clinical presentation of this patient was difficult to discriminate from that of ILD, and TBLB was useful in the differential diagnosis.

AB - We describe a 55-year-old man with advanced adenocarcinoma of the lung who received gefitinib ('IRESSA'). After gefitinib administration for 7 months, computed tomography scan of the chest demonstrated diffuse ground glass opacity and he was suspected to have developed gefitinib-induced interstitial lung disease (ILD). However, transbronchial lung biopsy (TBLB) revealed tumor cells in the middle-size lung vessels. Afterwards, multiple infarctions of the brain, spleen and left kidney were detected. Then, he was considered to have developed systemic tumor emboli, a rare complication. The clinical presentation of this patient was difficult to discriminate from that of ILD, and TBLB was useful in the differential diagnosis.

KW - Gefitinib

KW - Ground glass opacity

KW - NSCLC

KW - Transbronchial lung biopsy

KW - Tumor embolism

UR - http://www.scopus.com/inward/record.url?scp=27844452453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844452453&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.44.979

DO - 10.2169/internalmedicine.44.979

M3 - Article

C2 - 16258216

AN - SCOPUS:27844452453

SN - 0918-2918

VL - 44

SP - 979

EP - 982

JO - Internal Medicine

JF - Internal Medicine

IS - 9

ER -

Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this